Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population-Reference-Cited by-同舟云学术

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

Published:2013-10 Issue:11 Volume:14 Page:1067-1076
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sgroi Dennis C,Sestak Ivana,Cuzick Jack,Zhang Yi,Schnabel Catherine A,Schroeder Brock,Erlander Mark G,Dunbier Anita,Sidhu Kally,Lopez-Knowles Elena,Goss Paul E,Dowsett Mitch

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. Annual hazard rates of recurrence for breast cancer after primary therapy;Saphner;J Clin Oncol,1996

3. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial;Cuzick;Lancet Oncol,2010

4. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial;Lancet Oncol,2008

5. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up;Regan;Lancet Oncol,2011

Cited by 315 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images;2023-10-10

2. Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer;Breast Cancer;2023-10-09

3. Determinants of response to CDK4/6 inhibitors in the real-world setting;npj Precision Oncology;2023-09-13

4. Prognostic factors in Luminal B-like HER2-negative breast cancer tumors;Surgical Oncology;2023-08

5. Precision medicine in extended adjuvant endocrine therapy for breast cancer;Current Opinion in Oncology;2023-07-19